---
title: 'Outcomes of Older Adults and Frail Patients Receiving Idecabtagene Vicleucel:
  A CIBMTR Study'
date: '2025-01-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39786391/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20250110170832&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Idecabtagene vicleucel (ide-cel) is an anti-BCMA CAR-T cell therapy approved
  for patients with relapsed/refractory multiple myeloma (RRMM) after 2 prior lines
  of therapy. There is limited data on outcomes of CAR T in older adults and frail
  patients with RRMM. In this study, we utilized data from the Center for International
  Blood and Marrow Transplantation Registry to describe the safety and efficacy of
  ide-cel in these clinically important subgroups. An adapted version of the ...
disable_comments: true
---
Idecabtagene vicleucel (ide-cel) is an anti-BCMA CAR-T cell therapy approved for patients with relapsed/refractory multiple myeloma (RRMM) after 2 prior lines of therapy. There is limited data on outcomes of CAR T in older adults and frail patients with RRMM. In this study, we utilized data from the Center for International Blood and Marrow Transplantation Registry to describe the safety and efficacy of ide-cel in these clinically important subgroups. An adapted version of the ...